Core Insights - AngioDynamics (ANGO) has received expanded indications in Europe for its NanoKnife System, enhancing its clinical utility in soft tissue tumor ablation, specifically for tumors of the liver, pancreas, kidney, and prostate, including intermediate-risk prostate cancer cases [1][8]. Group 1: Expanded Indications and Clinical Utility - The broadened indications allow greater physician access to the NanoKnife System's irreversible electroporation (IRE) technology, which is particularly useful for treating tumors that are difficult to remove or located near vital anatomical structures [2][9]. - The management of ANGO noted increasing clinical adoption of the NanoKnife for prostate indications and aims for further global expansion, highlighting the broader applicability of its IRE technology [3][6]. Group 2: Clinical Evidence and Registry Launch - To support clinical adoption and generate longitudinal evidence, ANGO plans to launch the LIVER-IRE Global Registry in collaboration with the University of Manchester, which will assess real-world outcomes for patients treated with IRE for liver tumors [4][10]. - Clinical evidence for the NanoKnife System's IRE platform is growing, with data from trials indicating procedural success and promising outcomes in various malignancies, reinforcing the technology's safety and value [10][11]. Group 3: Market Position and Growth Potential - ANGO is positioned for significant growth following the European expansion, as broader approvals across multiple tumor types significantly increase its addressable market [6][12]. - Europe accounts for approximately 28% of global IRE procedure volumes, indicating its importance in the overall market and supporting the NanoKnife's multi-organ growth strategy [8][11]. Group 4: Industry Prospects - The tumor ablation market is projected to reach $2.47 billion by 2026, with a CAGR of 13.1% through 2035, driven by rising demand for minimally invasive therapies and advanced therapeutic options [13].

Core Insights - The global tumor ablation market is projected to grow from US$ 1.67 billion in 2024 to US$ 4.15 billion by 2032, indicating a significant growth trajectory [1]. By Technology - Radiofrequency ablation holds the largest revenue share in the tumor ablation market due to its specificity and efficiency in treating solid tumors in the liver, lung, and kidney [7]. - Microwave ablation technology is expected to experience the fastest growth, as it is effective in tissues with low electrical conductance [7]. - Cryoablation is gaining traction for treating tumors in the liver, kidneys, and prostate [7]. - High-intensity focused ultrasound (HIFU) and irreversible electroporation (IRE) are emerging modalities, with IRE being a minimally invasive outpatient procedure [7]. By Treatment Mode - Percutaneous ablation is the dominant treatment mode, offering faster recovery and minimal scarring [7]. - Surgical ablation remains a conventional and effective method for various tumor types [7]. - Laparoscopic ablation is anticipated to grow rapidly due to its precision in complex cases [7]. By Application - The liver cancer segment accounted for over 21% of the market share in 2024, driven by the high prevalence of liver cancer and a preference for minimally invasive treatments [7]. - Kidney cancer also holds a substantial market share, supported by the increasing prevalence and adoption of minimally invasive treatments [7]. - Prostate cancer and bone cancer are competing for significant shares in the tumor ablation market [8]. By End-User - Hospitals are the largest end-user segment due to their comprehensive healthcare services [14]. - Oncology centers also represent a significant share, focusing exclusively on cancer care with advanced technologies [14]. By Region - North America leads the tumor ablation market, supported by high healthcare expenditure and advanced medical technologies [14]. - Europe is the second-largest market, driven by an aging population and rising cancer prevalence [14]. - The Asia Pacific region is expected to grow the fastest, with emerging economies like China and India presenting untapped opportunities [14].